)

Bicara Therapeutics (BCAX) investor relations material
Bicara Therapeutics Morgan Stanley 23rd Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Program overview and scientific differentiation
Lead molecule ficerafusp alfa is a bifunctional EGFR-TGF-β1/3 inhibitor targeting tumor microenvironment for enhanced efficacy and immunotherapy-like response.
Tumor-targeted approach localizes TGF-β inhibition, reducing toxicity and improving outcomes, especially in EGFR-overexpressing, immunosuppressive tumors.
Focus is on HPV-negative recurrent/metastatic head and neck squamous cell carcinoma, a population with high unmet need and poor prognosis.
Combination with pembrolizumab has shown tripled response rates and doubled overall survival compared to standard care.
Activity is most pronounced in HPV-negative patients due to biological characteristics and disease etiology.
Clinical development and trial design
Phase 2/3 trial is designed as a seamless study to meet Project Optimus and Project Front Runner requirements, with interim and confirmatory analyses.
Enrollment is on track, with full enrollment expected by 2027, and strong investigator engagement following recent ASCO data.
Dose selection is informed by both blinded and open-label datasets, with upcoming data from the 750mg cohort to guide decisions.
Only HPV-negative patients are enrolled, reflecting the majority of the recurrent/metastatic population and aligning with companion diagnostic development.
Less frequent dosing regimens (every two weeks) are being explored, with bridging studies planned to support convenience at launch.
Regulatory and commercial strategy
Regulatory path aims for accelerated approval, with ongoing FDA dialogue and study design tailored to meet evolving agency expectations.
Companion diagnostic for HPV status is being developed to harmonize testing and streamline patient identification.
Addressable market is substantial, with HPV-negative cases dominating in the U.S., Europe, and Asia.
Commercial strategy anticipates a large market with room for multiple players, and strong conviction in the EGFR bifunctional class.
Cash runway exceeds $440 million, funding pivotal studies and key cohort expansions through confirmatory endpoints.
Next Bicara Therapeutics earnings date

Next Bicara Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage